Search Results - "Ruel, Chris"

Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma by Chow, Warren, Frankel, Paul, Ruel, Chris, Araujo, Dejka M., Milhem, Mohammed, Okuno, Scott, Hartner, Lee, Undevia, Samir, Staddon, Arthur

“…Background This single‐arm, multicenter, phase 2 study evaluated the safety and antitumor activity of pazopanib in patients with unresectable or metastatic…”
Get full text

Pazopanib in Patients with Osteosarcoma Metastatic to the Lung: Phase 2 Study Results and the Lessons for Tumor Measurement by Frankel, Paul, Ruel, Chris, Uche, An, Choy, Edwin, Okuno, Scott, Somiah, Neeta, Chow, Warren A.

“…Background. This single-arm, multicenter, phase 2 study evaluated the safety and antitumor activity of pazopanib in patients with unresectable, pulmonary…”
Get full text

Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies by Siddiqi, Tanya, Frankel, Paul, Beumer, Jan H., Kiesel, Brian F., Christner, Susan, Ruel, Chris, Song, Joo Y., Chen, Robert, Kelly, Kevin R., Ailawadhi, Sikander, Kaesberg, Paul, Popplewell, Leslie, Puverel, Sandrine, Piekarz, Richard, Forman, Stephen J., Newman, Edward M.

“…Alisertib, an Aurora kinase A inhibitor, was evaluated in a Phase 1 study in combination with the histone deacetylase inhibitor vorinostat, in patients with…”
Get full text

Phase 1 Study of MLN8237, an Aurora KinaseA (AURKA) Inhibitor, Combined with Vorinostat, a Histone Deacetylase (HDAC) Inhibitor, in Lymphoid Malignancies by Siddiqi, Tanya, Frankel, Paul, Ruel, Chris, Chen, Robert W, Kelly, Kevin R., Tuscano, Joseph, Popplewell, Leslie, Forman, Stephen J., Piekarz, Richard, Newman, Edward

“…Background: Amplification or overexpression of AURKA, a key mitotic regulator, is seen in various tumors and is associated with poor outcome in…”
Get full text

Results from a Phase 1 Study and Expanded Cohort of an Interrupted Dosing Schedule of the Aurora Kinase a Inhibitor MLN8237 Combined with Vorinostat in Lymphoid Malignancies by Siddiqi, Tanya, Scuto, Anna, Beumer, Jan H., Song, Joo Y., Frankel, Paul, Ruel, Chris, Cobb, Jacob, Kiesel, Brian F., Weisenburger, Dennis D., Kelly, Kevin R., Tuscano, Joseph, Popplewell, Leslie, Forman, Stephen J., Piekarz, Richard, Newman, Edward M.

“…Background MLN8237 is an oral inhibitor of aurora kinase A (AURKA) that causes mitotic spindle defects, mitotic delay, and apoptosis in lymphoma cell lines and…”
Get full text